NASDAQ:SERA - Nasdaq - US81749D1072 - Common Stock - Currency: USD
Overall SERA gets a fundamental rating of 3 out of 10. We evaluated SERA against 559 industry peers in the Biotechnology industry. While SERA seems to be doing ok healthwise, there are quite some concerns on its profitability. SERA is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.96% | ||
ROE | -34.73% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 8.7% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -2.68 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.04 | ||
Quick Ratio | 2.04 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.55
-0.05 (-3.12%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 507.73 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.61 | ||
P/tB | 0.62 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.96% | ||
ROE | -34.73% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 8.7% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 46.43% | ||
Cap/Sales | 339.13% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.04 | ||
Quick Ratio | 2.04 | ||
Altman-Z | -2.68 |